Morpholine → HCID 44545155, 화합물

HRID 1692669노트

반응식

C(OC([NH:8][C:9]1[N:14]=[CH:13][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26]([OH:28])=O)=[C:17]([N:29]3[CH2:34][CH2:33][O:32][CH2:31][CH2:30]3)[N:16]=2)=[CH:11][N:10]=1)=O)(C)(C)C.[NH:35]1[CH2:40][CH2:39][O:38][CH2:37][CH2:36]1>>[NH2:8][C:9]1[N:10]=[CH:11][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26]([N:35]3[CH2:40][CH2:39][O:38][CH2:37][CH2:36]3)=[O:28])=[C:17]([N:29]3[CH2:30][CH2:31][O:32][CH2:33][CH2:34]3)[N:16]=2)=[CH:13][N:14]=1

참가 물질

반응물 2

HCID 8083Morpholine

HCID 66909826HCID 66909826, 화합물

생성물 1

HCID 44545155HCID 44545155, 화합물

실험 절차

3-(2-(2-(Tert-butoxycarbonylamino)pyrimidin-5-yl)-6-morpholino-9H-purin-9-yl)propanoic acid (50 mg) was reacted with morpholine via General Procedure F followed by Boc deprotection via General Procedure E to give 24.9 mg 113 as white solid following reverse phase purification. MS (Q1) 440.2 (M)+

후처리

customto give
custom24.9 mg 113 as white solid following reverse phase purification

출처 및 근거

ORD 기록: ord-2e25a14371b3443396b5ef1293af0af7
출처 데이터셋: uspto-grants-2012_04
DOI: 10.6084/m9.figshare.5104873.v1
특허 번호: US08158624B2

반응 노트

불러오는 중…